Serum endotrophin identifies optimal responders to PPARγ agonists in type 2 diabetes

Diabetologia

Volumn 60, Issue 1, 2017, Pages 50-59

  Karsdal, Morten A ^a   Henriksen, Kim ^a   Genovese, Federica ^a   Leeming, Diana J ^a   Nielsen, Mette J ^a   Riis, Bente J ^a   Christiansen, Claus ^a,b   Byrjalsen, Inger ^a   Schuppan, Detlef ^c,d  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Balaglitazone; Efficacy; PPAR ; Safety; Type 2 diabetes

Indexed keywords

ADIPOCYTOKINE; BALAGLITAZONE; ENDOTROPHIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PIOGLITAZONE; PLACEBO; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; COLLAGEN TYPE 6; GLUCOSE BLOOD LEVEL; PEPTIDE FRAGMENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; QUINAZOLINE DERIVATIVE;

ADIPOSE TISSUE; ADULT; ARTICLE; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; FATTY LIVER; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; INSULIN RESISTANCE; INSULIN TREATMENT; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK BENEFIT ANALYSIS; TREATMENT RESPONSE; AGED; AGONISTS; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADIPOSE TISSUE; AGED; BLOOD GLUCOSE; COLLAGEN TYPE VI; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PPAR GAMMA; QUINAZOLINES; THIAZOLIDINEDIONES;

EID: 84986309974     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-4094-1     Document Type: Article

References (46)

1. World Health Organization (2008) Diabetes. Fact sheet no 312. World Health Organization, Geneva
2. Krentz AJ, Patel MB, Bailey CJ (2008) New drugs for type 2 diabetes mellitus: what is their place in therapy? Drugs 68:2131–2162
3. Karsdal MA, Manon-Jensen T, Genovese F et al (2015) Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 308:G807–G830
4. Park J, Scherer PE (2012) Adipocyte-derived endotrophin promotes malignant tumor progression. J Clin Invest 122:4243–4256
5. Mak KM, Sehgal P, Harris CK (2014) Type VI collagen: its biology and value as a biomarker of hepatic fibrosis. Austin Biomark Diagn 1:id1012
6. Aigner T, Hambach L, Soder S, Schlotzer-Schrehardt U, Poschl E (2002) The C5 domain of COL6A3 is cleaved off from the Col6 fibrils immediately after secretion. Biochem Biophys Res Commun 290:743–748
7. Lamande SR, Morgelin M, Adams NE, Selan C, Allen JM (2006) The C5 domain of the collagen VI alpha3(VI) chain is critical for extracellular microfibril formation and is present in the extracellular matrix of cultured cells. J Biol Chem 281:16607–16614
8. Sun K, Park J, Gupta OT et al (2014) Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction. Nat Commun 5:3485
9. Dankel SN, Svard J, Mattha S et al (2014) COL6A3 expression in adipocytes associates with insulin resistance and depends on PPARγ and adipocyte size. Obesity (Silver Spring) 22:1807–1813
10. Park J, Scherer PE (2013) Endotrophin in the tumor stroma: a new therapeutic target for breast cancer? Expert Rev Anticancer Ther 13:111–113
11. Khan T, Muise ES, Iyengar P et al (2009) Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol Cell Biol 29:1575–1591
12. Pasarica M, Gowronska-Kozak B, Burk D et al (2009) Adipose tissue collagen VI in obesity. J Clin Endocrinol Metab 94:5155–5162
13. Cho N, Momose Y (2008) Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress. Curr Top Med Chem 8:1483–1507
14. Charbonnel B, DeFronzo R, Davidson J et al (2010) Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). J Clin Endocrinol Metab 95:2163–2171
15. Home PD, Pocock SJ, Beck-Nielsen H et al (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373:2125–2135
16. Takada I, Suzawa M, Matsumoto K, Kato S (2007) Suppression of PPAR transactivation switches cell fate of bone marrow stem cells from adipocytes into osteoblasts. Ann N Y Acad Sci 1116:182–195
17. Karalliedde J, Buckingham RE (2007) Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Drug Saf 30:741–753
18. Soroceanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC (2004) Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 183:203–216
19. Berger JP, Akiyama TE, Meinke PT (2005) PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 26:244–251
20. Agrawal R, Jain P, Dikshit SN (2012) Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist. Mini Rev Med Chem 12:87–97
21. Larsen PJ, Lykkegaard K, Larsen LK et al (2008) Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-γ) agonist balaglitazone. Eur J Pharmacol 596:173–179
22. Sun S, Henriksen K, Karsdal MA et al (2015) Collagen type III and VI turnover in response to long-term immobilization. PLoS One 10, e0144525
23. Henriksen K, Byrjalsen I, Qvist P et al (2011) Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy. Diabetes Metab Res Rev 27:392–401
24. Feigh M, Henriksen K, Andreassen KV et al (2011) A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet-induced obese rats. Diabetes Obes Metab 13:911–920
25. Bedogni G, Bellentani S, Miglioli L et al (2006) The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6:33
26. Park J, Morley TS, Scherer PE (2013) Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours. EMBO Mol Med 5:935–948
27. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298:1180–1188
28. Erdmann E, Charbonnel B, Wilcox RG et al (2007) Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 30:2773–2778
29. Singh S, Loke YK, Furberg CD (2007) Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298:1189–1195
30. McDonough AK, Rosenthal RS, Cao X, Saag KG (2008) The effect of thiazolidinediones on BMD and osteoporosis. Nat Clin Pract Endocrinol Metab 4:507–513
31. Douglas IJ, Evans SJ, Pocock S, Smeeth L (2009) The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med 6, e1000154
32. Bell LN, Wang J, Muralidharan S et al (2012) Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. Hepatology 56:1311–1318
33. Sanyal AJ, Chalasani N, Kowdley KV et al (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362:1675–1685
34. Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L (2015) Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology 61:1392–1405
35. Griffiths MR, Shepherd M, Ferrier R, Schuppan D, James OF, Burt AD (1992) Light microscopic and ultrastructural distribution of type VI collagen in human liver: alterations in chronic biliary disease. Histopathology 21:335–344
36. Burt AD, Griffiths MR, Schuppan D, Voss B, MacSween RN (1990) Ultrastructural localization of extracellular matrix proteins in liver biopsies using ultracryomicrotomy and immuno-gold labelling. Histopathology 16:53–58
37. Veidal SS, Karsdal MA, Vassiliadis E et al (2011) MMP mediated degradation of type VI collagen is highly associated with liver fibrosis—identification and validation of a novel biochemical marker assay. PLoS One 6, e24753
38. Lebensztejn DM, Sobaniec-Lotowska ME, Kaczmarski M, Voelker M, Schuppan D (2006) Matrix-derived serum markers in monitoring liver fibrosis in children with chronic hepatitis B treated with interferon alpha. World J Gastroenterol 12:3338–3343
39. Lebensztejn DM, Sobaniec-Lotowska ME, Bauer M, Kaczmarski M, Voelker M, Schuppan D (2005) Serum fibrosis markers as predictors of an antifibrotic effect of interferon alfa in children with chronic hepatitis B. Eur J Gastroenterol Hepatol 17:843–848
40. Stickel F, Urbaschek R, Schuppan D et al (2001) Serum collagen type VI and XIV and hyaluronic acid as early indicators for altered connective tissue turnover in alcoholic liver disease. Dig Dis Sci 46:2025–2032
41. Shahin M, Schuppan D, Waldherr R et al (1992) Serum procollagen peptides and collagen type VI for the assessment of activity and degree of hepatic fibrosis in schistosomiasis and alcoholic liver disease. Hepatology 15:637–644
42. Leeming DJ, Karsdal MA, Byrjalsen I et al (2013) Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension. Aliment Pharmacol Ther 38:1086–1096
43. Lampe AK, Bushby KM (2005) Collagen VI related muscle disorders. J Med Genet 42:673–685
44. Lampe AK, Zou Y, Sudano D et al (2008) Exon skipping mutations in collagen VI are common and are predictive for severity and inheritance. Hum Mutat 29:809–822
45. Bonaldo P, Braghetta P, Zanetti M, Piccolo S, Volpin D, Bressan GM (1998) Collagen VI deficiency induces early onset myopathy in the mouse: an animal model for Bethlem myopathy. Hum Mol Genet 7:2135–2140
46. Bushby KM, Collins J, Hicks D (2014) Collagen type VI myopathies. Adv Exp Med Biol 802:185–199